Capsid Assembly Inhibitor Crystal Form for cccDNA Persistence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic hepatitis B, such as interferon and nucleoside analogues, are ineffective in eliminating covalently closed circular DNA (cccDNA) in hepatocytes, limiting cure rates due to the persistence of this viral reservoir.
Innovation Solution
Development of a crystalline form of a capsid protein assembly inhibitor containing a five-membered N heterocycle, which can be formulated into a pharmaceutical composition to prevent or treat hepatitis B by inhibiting capsid protein assembly, thereby blocking virus replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (interferon and nucleoside analogues) are used, then viral replication is suppressed, but cccDNA in hepatocytes persists and cannot be eliminated
Solution Approach 1:
The patent targets and extracts/inhibits the formation of the viral capsid structure that protects cccDNA, using small molecule compounds (Formula I) that bind to core proteins and prevent capsid assembly, thereby exposing and enabling elimination of the viral reservoir without affecting the cccDNA directly
Solution Approach 2:
The patent introduces an intermediary mechanism by blocking capsid protein assembly as a middle step between viral replication suppression and cccDNA elimination. By inhibiting the capsid formation process (using compounds that bind to core proteins), the patent creates a pathway to eliminate the protected viral genome that would otherwise persist
2Reliability
If pyrrole derivative compounds are developed to inhibit capsid assembly, then new therapeutic efficacy is achieved, but crystalline form stability and pharmaceutical properties must be ensured
Solution Approach 1:
The patent applies parameter changes by identifying and characterizing specific crystalline forms (Form I and Form II) with distinct XRPD patterns and DSC properties. By optimizing crystallization parameters (solvent selection, temperature, pH) and characterizing physical properties (melting point, diffraction patterns), the patent ensures pharmaceutical stability while maintaining biological efficacy
Solution Approach 2:
The patent creates composite pharmaceutical formulations by combining the active pyrrole derivative compound with excipients in specific ratios and configurations. The defined crystalline forms represent composite structures where the active ingredient is stabilized within a crystal lattice, providing both efficacy and stability
Data Source
Figure 1~2
Figure 3~4
AI summary
Disclosed by the present application is a crystalline form of a capsid protein assembly inhibitor containing an N hetero five-membered ring; specifically disclosed is the crystalline form of the compound of formula I; also comprised is an the application of said crystalline form in the preparation of a drug for preventing or treating diseases benefiting from the inhibition of capsid protein assembly.